Studies Addressing Rare Neurodegenerative Diseases including ALS
Last verified by NonDilute: 2026-04-29. Official notice and agency instructions control.
If you're running neuroscience research on ALS or rare neurodegeneration, FDA is actively funding studies that can influence regulatory policy and accelerate treatments.
Report stale or inaccurate summary
What this is
This FDA funding opportunity supports research into rare neurodegenerative diseases with emphasis on ALS. The program is designed to generate evidence that can guide FDA regulatory decisions and accelerate therapeutic development for diseases with limited treatment options. Applicants should have research capacity to conduct rigorous studies on disease mechanisms, biomarkers, or clinical outcomes relevant to ALS and related rare neurological conditions. Exact budget, eligible entity types, and application deadlines require consulting the full RFP.
Who can apply
Eligibility details are not specified in this notice. Likely restricted to research institutions, universities, and non-profits with IRB approval and clinical research capacity; verify full RFP for organizational type, geographic, and size restrictions.
Topics: ALS research · rare neurodegenerative disease · FDA funding · clinical studies · drug development · biomarkers
Public-source funding discovery only. This summary is generated from public agency data and may be incomplete or stale. NonDilute is not affiliated with, endorsed by, or acting on behalf of any government agency. Official notices and agency instructions control. NonDilute does not determine eligibility, provide grant-writing advice, or guarantee funding.